title: [Endocrine therapy in breast cancer: efficacy and adverse events].
abstract: Endocrine therapy remains a mainstay in the treatment of endocrine-sensitive breast cancer. In the adjuvant setting, 5 years of endocrine therapy significantly reduces recurrence rate and mortality. Tamoxifen is the molecule of choice for premenopausal women, whereas for postmenopausal women aromatase inhibitors are currently part of the standard treatment. Endocrine therapy can induce side effects, which can affect patient's quality of life and lead to premature treatment interruption. Identification and adequately addressing these side effects is fundamental to maintain good treatment compliance and therefore improve breast cancer specific outcome.
authors.affiliation: Département d'oncologie, CHUV, 1011 Lausanne. rahel.odermatt@chuv.ch
authors.forename: Rahel
authors.initials: R
authors.lastname: Odermatt
authors.forename: Anita
authors.initials: A
authors.lastname: Wolfer
authors.forename: Khalil
authors.initials: K
authors.lastname: Zaman
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans
chemical_list: D018931:Antineoplastic Agents, Hormonal